Cenk Sumen is an internationally recognized expert in advanced therapies. He has served in technical and business management roles of increasing responsibility for Thermo Fisher Scientific, Hitachi Chemical Advanced Therapeutics Solutions, PerkinElmer, Stemcell Technologies, Life Technologies, and Invitrogen, specializing in building innovation partnerships, advancing process development, and establishing sustainable manufacturing platforms. Dr. Sumen received his BS in biology from Massachusetts Institute of Technology, and his Ph.D. in microbiology and immunology from Leland Stanford Junior University, and he currently teaches as an Adjunct Professor at New York University Tandon School of Engineering.